Literature DB >> 16292351

Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.

L P Le1, A A Rivera, J N Glasgow, V V Ternovoi, H Wu, M Wang, B F Smith, G P Siegal, D T Curiel.   

Abstract

The full realization of conditionally replicative adenoviruses (CRAds) for cancer therapy has been hampered by the limited knowledge of CRAd function in vivo and particularly in an immunocompetent host. To address this issue, we previously proposed a canine adenovirus type 2 (CAV2)-based CRAd for clinical evaluation in canine patients with osteosarcoma (OS). In this study, we evaluated infectivity-enhancement strategies to establish the foundation for designing a potent CAV2 CRAd with effective transduction capacity in dog osteosarcoma cells. The results indicate that the native CAV2 fiber-knob can mediate increased binding, and consequently gene transfer, in both canine osteosarcoma immortalized and primary cell lines relative to previously reported Ad5 infectivity-enhancement strategies. Gene delivery was further enhanced by incorporating a polylysine polypeptide onto the carboxy terminus of the CAV2 knob. This vector demonstrated improved gene delivery in osteosarcoma xenograft tumors. These data provide the rationale for generation of infectivity-enhanced syngeneic CAV2 CRAds for clinical evaluation in a dog osteosarcoma model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16292351     DOI: 10.1038/sj.gt.3302674

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  Imaging and drug delivery using theranostic nanoparticles.

Authors:  Siti M Janib; Ara S Moses; J Andrew MacKay
Journal:  Adv Drug Deliv Rev       Date:  2010-08-13       Impact factor: 15.470

Review 2.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

3.  Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.

Authors:  Ivaylo Gentschev; Sandeep S Patil; Marion Adelfinger; Stephanie Weibel; Ulrike Geissinger; Alexa Frentzen; Nanhai G Chen; Yong A Yu; Qian Zhang; Gregory Ogilvie; Aladar A Szalay
Journal:  Bioengineered       Date:  2012-10-23       Impact factor: 3.269

Review 4.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

Review 5.  Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.

Authors:  Sandeep S Patil; Ivaylo Gentschev; Ingo Nolte; Gregory Ogilvie; Aladar A Szalay
Journal:  J Transl Med       Date:  2012-01-04       Impact factor: 5.531

Review 6.  Oncolytic virotherapy of canine and feline cancer.

Authors:  Ivaylo Gentschev; Sandeep S Patil; Ivan Petrov; Joseph Cappello; Marion Adelfinger; Aladar A Szalay
Journal:  Viruses       Date:  2014-05-16       Impact factor: 5.048

7.  Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.

Authors:  Amy L MacNeill; Kristen M Weishaar; Bernard Séguin; Barbara E Powers
Journal:  Viruses       Date:  2018-07-28       Impact factor: 5.048

8.  Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Ashley S Harms; David G Standaert; David T Curiel
Journal:  Viruses       Date:  2014-08-21       Impact factor: 5.048

Review 9.  On the potential of oncolytic virotherapy for the treatment of canine cancers.

Authors:  Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2015-08-26

Review 10.  Oncolytic Viruses for Canine Cancer Treatment.

Authors:  Diana Sánchez; Gabriela Cesarman-Maus; Alfredo Amador-Molina; Marcela Lizano
Journal:  Cancers (Basel)       Date:  2018-10-27       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.